drugset / Trial / NCT01088464
Study of IMC-11F8 in Participants With Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is to establish the safety and pharmacokinetic (PK) profile of IMC-11F8, administered either: (1) in a 3-week cycle; or (2) in a 2-week cycle to Japanese participants with advanced solid tumors who have not responded to standard therapy or for whom no standard therapy is available.
Timeline
- Start
- 2010-01
- Primary completion
- 2012-02
- Completion
- 2012-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Necitumumab | Monoclonal antibody | 600 mg | Intravenous |
| Subject | Necitumumab | Monoclonal antibody | 800 mg | Intravenous |